


DESIGNER OPIOIDS PANEL



Updated Designer Opioids Panel Key Features & Benefits

- Latest, most relevant emergent designer opioid analytes
- Quantitative blood results
- Lower limit of detection to ensure no missed results
- Improved reporting
- Quicker turnaround time

BECAUSE NOT ALL OPIATES ARE CREATED EQUAL...

58% of samples tested with the Designer Opioids panel were found positive for one or more analytes[#]. Axis recommends ordering this panel for all fatalities that have circumstances consistent with Opioid use or intravenous drug abuse and negative routine blood toxicology for opiates/opioids such as 6-acetylmorphine, morphine, and fentanyl.

[#]Data Source: Axis analyzed 1,408 blood specimens for the presence of fentanyl analogs and designer opioid analytes using LC/MS/MS between July 2016 and July 2017.

ORDER CODE: 13810			
SAMPLE TYPE: Blood, Serum*, Urine*, Vitreous*			
MINIMUM SAMPLE VOLUME: 0.5 mL (2mL preferred)			
COMPOUND NAME	REPORTING LIMIT	COMPOUND NAME	REPORTING LIMIT
Acetylfentanyl	50 pg/mL	Fluorofentanyl	0.5 ng/mL*
Acrylfentanyl	50 pg/mL	Furanylfentanyl	50 pg/mL
Beta-hydroxythiofentanyl	50 pg/mL	Methoxyacetylfentanyl	50 pg/mL
Butyrylfentanyl/ Isobutyrylfentanyl	50 pg/mL	Ocfentanil	50 pg/mL
Carfentanil	10 pg/mL**	Para-fluorobutyrylfentanyl/Para-fluoroisobutyrylfentanyl	50 pg/mL
cis-3-Methylfentanyl	50 pg/mL	Tetrahydrofuranfentanyl	50 pg/mL
Cyclopropylfentanyl	50 pg/mL	U47700	50 pg/mL

*Results qualitatively reported **Results reported qualitatively 10-20 pg/mL

Version 5.0 Effective Date: 1/22/2024